Obesity and related metabolic diseases are major problems worldwide. Some probiotics are currently considered potential therapeutic strategies for obesity. We aimed to investigate the anti-obesity efficacy of Latilactobacillus sakei WIKIM31 in obese mice induced by a high fat diet. The administration of a high-fat diet with L. sakei WIKIM31 reduced body weight gain, epididymal fat mass, triglyceride and total cholesterol levels in the blood, and remarkably decreased the expression of lipogenesis-related genes in the epididymal adipose tissue and liver. Interestingly, intake of L. sakei WIKIM31 improved gut barrier function by increasing the gene expression of tight junction proteins and suppressing the inflammatory responses. Additionally, L. sakei WIKIM31 enhanced the production of short-chain fatty acids, such as butyrate and propionate, in the intestinal tract. These results showed that L. sakei WIKIM31 can be used as a potential therapeutic probiotic for obesity.

中文翻译：

---

Latilactobacillus sakei WIKIM31 通过调节脂质代谢和抑制炎症来减缓高脂肪饮食诱导的肥胖小鼠的体重增加。

肥胖和相关的代谢疾病是世界范围内的主要问题。一些益生菌目前被认为是潜在的肥胖治疗策略。我们旨在研究清酒乳杆菌 WIKIM31 对高脂肪饮食诱导的肥胖小鼠的抗肥胖功效。用L.sakei WIKIM31 给予高脂肪饮食可减少体重增加、附睾脂肪量、甘油三酯和血液中的总胆固醇水平，并显着降低附睾脂肪组织和肝脏中脂肪生成相关基因的表达。有趣的是，摄入L.sakei WIKIM31 通过增加紧密连接蛋白的基因表达和抑制炎症反应来改善肠道屏障功能。此外，L. sakei WIKIM31 增强了肠道中丁酸和丙酸等短链脂肪酸的产生。这些结果表明L.sakei WIKIM31 可用作治疗肥胖症的潜在益生菌。